Search

Your search keyword '"Mitsuyama, Keiichi"' showing total 565 results

Search Constraints

Start Over You searched for: Author "Mitsuyama, Keiichi" Remove constraint Author: "Mitsuyama, Keiichi"
565 results on '"Mitsuyama, Keiichi"'

Search Results

1. AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

3. Adrenomedullin for steroid-resistant ulcerative colitis: a randomized, double-blind, placebo-controlled phase-2a clinical trial

4. Antibodies to Crohn’s disease peptide 353 as a diagnostic marker for pediatric Crohn’s disease: a prospective multicenter study in Japan

5. Symptoms Contributing to the Diagnosis of Small Bowel Tumors

6. Clinical and Pharmacokinetic Factors Associated With Adalimumab-Induced Mucosal Healing in Patients With Crohn’s Disease

7. Efficacy of Indigo Naturalis in a Multicenter Randomized Controlled Trial of Patients With Ulcerative Colitis

8. Pyoderma gangrenosum, acne, and unclassified inflammatory bowel disease syndrome: A case report on a new subtype of pyogenic arthritis, pyoderma gangrenosum, and acne syndrome

10. Serum leucine‐rich alpha‐2 glycoprotein and calprotectin in children with inflammatory bowel disease: a multicenter study in Japan

13. Utility of Diagnostic Colonoscopy in Pediatric Intestinal Disease

15. Adrenomedullin for biologic‐resistant Crohn's disease: A randomized, double‐blind, placebo‐controlled phase 2a clinical trial

16. AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

17. Significance of measurement of serum trough level and anti‐drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohnʼs disease: a subanalysis of the DIAMOND trial

19. Lean/normal‐weight metabolic dysfunction‐associated fatty liver disease is a risk factor for reflux esophagitis

20. Tu1499: THE REAL-WORLD EFFECTIVENESS AND SAFETY OF CORTICOSTERIDS, CALCINEURIN INHIBITOR, BIOLOGICS, AND JAK INHIBITOR IN HOSPITALIZED PATIENTS WITH ULCERATIVE COLITIS

21. Role of Serum Proteinase 3 Antineutrophil Cytoplasmic Antibodies in the Diagnosis, Evaluation of Disease Severity, and Clinical Course of Ulcerative Colitis

24. Possible diagnostic role of antibodies to Crohn’s disease peptide (ACP): results of a multicenter study in a Japanese cohort

28. Contributors

30. Non-Obese MAFLD Is Associated with Colorectal Adenoma in Health Check Examinees: A Multicenter Retrospective Study

34. Therapeutic Potential of a Self-Assembling Peptide Hydrogel to Treat Colonic Injuries Associated with Inflammatory Bowel Disease

35. Evaluation of Serum Leucine-Rich Alpha-2 Glycoprotein as a New Inflammatory Biomarker of Inflammatory Bowel Disease

39. Altered serum profile of the interleukin-22 system in inflammatory bowel disease

41. Adrenomedullin for steroid-resistant ulcerative colitis: a randomized, double-blind, placebo-controlled phase-2a clinical trial

42. Diagnostic accuracy of serum proteinase 3 antineutrophil cytoplasmic antibodies in children with ulcerative colitis

45. Treatment of ulcerative colitis by feeding with germinated barley foodstuff: first report of a multicenter open control trial

47. Curcumin Maintenance Therapy for Ulcerative Colitis: Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial

Catalog

Books, media, physical & digital resources